BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 11513138)

  • 1. Strategies for target cell recognition by natural killer cells.
    Diefenbach A; Raulet DH
    Immunol Rev; 2001 Jun; 181():170-84. PubMed ID: 11513138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity.
    Diefenbach A; Jensen ER; Jamieson AM; Raulet DH
    Nature; 2001 Sep; 413(6852):165-71. PubMed ID: 11557981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
    Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
    Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer.
    Cerwenka A; Lanier LL
    Tissue Antigens; 2003 May; 61(5):335-43. PubMed ID: 12753652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions.
    Sutherland CL; Chalupny NJ; Cosman D
    Immunol Rev; 2001 Jun; 181():185-92. PubMed ID: 11513139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The NKG2D receptor and its ligands-recognition beyond the "missing self"?
    Watzl C
    Microbes Infect; 2003 Jan; 5(1):31-7. PubMed ID: 12593971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages.
    Diefenbach A; Jamieson AM; Liu SD; Shastri N; Raulet DH
    Nat Immunol; 2000 Aug; 1(2):119-26. PubMed ID: 11248803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UL16 binding proteins.
    Cao W; He W
    Immunobiology; 2004; 209(3):283-90. PubMed ID: 15518340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.
    Bauer S; Groh V; Wu J; Steinle A; Phillips JH; Lanier LL; Spies T
    Science; 1999 Jul; 285(5428):727-9. PubMed ID: 10426993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NKG2D receptor-mediated NK cell function is regulated by inhibitory Ly49 receptors.
    Regunathan J; Chen Y; Wang D; Malarkannan S
    Blood; 2005 Jan; 105(1):233-40. PubMed ID: 15328154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystal structure of the Ly49I natural killer cell receptor reveals variability in dimerization mode within the Ly49 family.
    Dimasi N; Sawicki MW; Reineck LA; Li Y; Natarajan K; Margulies DH; Mariuzza RA
    J Mol Biol; 2002 Jul; 320(3):573-85. PubMed ID: 12096910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligands for natural killer cell receptors: redundancy or specificity.
    Cerwenka A; Lanier LL
    Immunol Rev; 2001 Jun; 181():158-69. PubMed ID: 11513137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The innate immune response to tumors and its role in the induction of T-cell immunity.
    Diefenbach A; Raulet DH
    Immunol Rev; 2002 Oct; 188():9-21. PubMed ID: 12445277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NKG2D-independent suppression of T cell proliferation by H60 and MICA.
    Kriegeskorte AK; Gebhardt FE; Porcellini S; Schiemann M; Stemberger C; Franz TJ; Huster KM; Carayannopoulos LN; Yokoyama WM; Colonna M; Siccardi AG; Bauer S; Busch DH
    Proc Natl Acad Sci U S A; 2005 Aug; 102(33):11805-10. PubMed ID: 16091471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular competition for NKG2D: H60 and RAE1 compete unequally for NKG2D with dominance of H60.
    O'Callaghan CA; Cerwenka A; Willcox BE; Lanier LL; Bjorkman PJ
    Immunity; 2001 Aug; 15(2):201-11. PubMed ID: 11520456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promiscuity and the single receptor: NKG2D.
    Eagle RA; Trowsdale J
    Nat Rev Immunol; 2007 Sep; 7(9):737-44. PubMed ID: 17673918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor.
    Zhou H; Luo Y; Lo JF; Kaplan CD; Mizutani M; Mizutani N; Lee JD; Primus FJ; Becker JC; Xiang R; Reisfeld RA
    Proc Natl Acad Sci U S A; 2005 Aug; 102(31):10846-51. PubMed ID: 16040807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
    Song H; Kim J; Cosman D; Choi I
    Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family.
    Steinle A; Li P; Morris DL; Groh V; Lanier LL; Strong RK; Spies T
    Immunogenetics; 2001; 53(4):279-87. PubMed ID: 11491531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts.
    Ogasawara K; Benjamin J; Takaki R; Phillips JH; Lanier LL
    Nat Immunol; 2005 Sep; 6(9):938-45. PubMed ID: 16086018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.